Azra Raza

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. doi request reprint The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes
    Azra Raza
    Myelodysplastic Syndromes Center, Columbia University Medical Center, Milstein Hospital Building, 6N 435, 177 Fort Washington Avenue, New York, New York 10032, USA
    Nat Rev Cancer 12:849-59. 2012
  2. doi request reprint A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome
    Azra Raza
    Columbia University Medical Center, Milstein Hospital Bldg, 6N 435, 177 Fort Washington Avenue, New York, NY 10032, USA
    Cancer 118:2138-47. 2012
  3. pmc Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Azra Raza
    Columbia University Medical Center, New York, NY, USA
    J Hematol Oncol 5:18. 2012
  4. pmc Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
    Naomi Galili
    Department of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY 10032, USA
    J Hematol Oncol 5:20. 2012
  5. doi request reprint Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays
    Naomi Galili
    St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York, NY 10011, USA
    Best Pract Res Clin Haematol 22:223-37. 2009
  6. pmc Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo
    Jingping Hu
    Laboratory of Membrane Biology, New York Blood Center, New York, NY
    Blood 121:3246-53. 2013
  7. doi request reprint MDS: Refining existing therapy through improved biologic insights
    Jordan Schecter
    The MDS Center at Columbia University, New York, NY, USA
    Blood Rev 26:73-80. 2012
  8. doi request reprint Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
    Azra Raza
    St Vincent s Comprehensive Cancer Center, New York, NY, USA
    Leuk Lymphoma 50:1336-44. 2009
  9. doi request reprint Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia
    Azra Raza
    Department of Medicine, St Vincent s Comprehensive Cancer Center, New York, New York 10011, USA
    Cancer 113:1596-604. 2008
  10. doi request reprint Prognosis in myelodysplastic syndromes: are the new classifications useful?
    Naomi Galili
    St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Curr Hematol Malig Rep 3:19-22. 2008

Detail Information

Publications11

  1. doi request reprint The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes
    Azra Raza
    Myelodysplastic Syndromes Center, Columbia University Medical Center, Milstein Hospital Building, 6N 435, 177 Fort Washington Avenue, New York, New York 10032, USA
    Nat Rev Cancer 12:849-59. 2012
    ..Although emerging insights establish an association between molecular abnormalities and the phenotypic heterogeneity of MDS, their origin and progression remain enigmatic...
  2. doi request reprint A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome
    Azra Raza
    Columbia University Medical Center, Milstein Hospital Bldg, 6N 435, 177 Fort Washington Avenue, New York, NY 10032, USA
    Cancer 118:2138-47. 2012
    ..This study evaluated 2 extended dose schedules of oral ezatiostat in 89 heavily pretreated patients with low to intermediate-1 risk myelodysplastic syndrome (MDS)...
  3. pmc Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Azra Raza
    Columbia University Medical Center, New York, NY, USA
    J Hematol Oncol 5:18. 2012
    ..Ezatiostat, a glutathione S-transferase P1-1 inhibitor, promotes the maturation of hematopoietic progenitors and induces apoptosis in cancer cells...
  4. pmc Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
    Naomi Galili
    Department of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY 10032, USA
    J Hematol Oncol 5:20. 2012
    ..The success of that study was based in part on the fact that the profile for response was linked to the biology of the disease...
  5. doi request reprint Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays
    Naomi Galili
    St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York, NY 10011, USA
    Best Pract Res Clin Haematol 22:223-37. 2009
    ..These biologic and clinical insights are providing the framework on which to build a new model of these diseases which, despite their heterogeneity, manifest certain unifying themes...
  6. pmc Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo
    Jingping Hu
    Laboratory of Membrane Biology, New York Blood Center, New York, NY
    Blood 121:3246-53. 2013
    ....
  7. doi request reprint MDS: Refining existing therapy through improved biologic insights
    Jordan Schecter
    The MDS Center at Columbia University, New York, NY, USA
    Blood Rev 26:73-80. 2012
    ..We expect that through advancing biologic insights, the use of such therapies will become more selective and refined...
  8. doi request reprint Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
    Azra Raza
    St Vincent s Comprehensive Cancer Center, New York, NY, USA
    Leuk Lymphoma 50:1336-44. 2009
    ..In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity...
  9. doi request reprint Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia
    Azra Raza
    Department of Medicine, St Vincent s Comprehensive Cancer Center, New York, New York 10011, USA
    Cancer 113:1596-604. 2008
    ..Eventually, 30% of patients with MDS will progress and develop acute myeloid leukemia (AML). New strategies are needed for these patients...
  10. doi request reprint Prognosis in myelodysplastic syndromes: are the new classifications useful?
    Naomi Galili
    St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Curr Hematol Malig Rep 3:19-22. 2008
    ..Clinical symptoms and degree of transfusion dependency will dictate the degree of therapeutic intervention...
  11. pmc Isolation of specific and biologically active peptides that bind cells from patients with acute myeloid leukemia (AML)
    Naomi Galili
    Saint Vincent s Comprehensive Cancer Center, New York, NY, USA
    J Hematol Oncol 1:8. 2008
    ....